Broker says this ASX 300 healthcare share can rise 60% in 12 months

Here's why this broker is feeling exceptionally bullish on this share.

| More on:
a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There could be some very big gains ahead for Clinuvel Pharmaceuticals Limited (ASX: CUV) shares according to the team at Bell Potter.

Its analysts have just initiated coverage on the ASX 300 healthcare share with a valuation significantly higher than current levels.

What is the broker saying about this ASX 300 healthcare share?

According to the note, the broker believes there's a lot to like about the company.

It highlights that Clinuvel is "one of very few ASX-listed biopharma companies directly commercialising novel pharmaceuticals across the US and EU in a highly profitable manner."

This is of course through the company's Scenesse product. It is the only approved treatment for patients suffering from a rare inherited disease called erythropoietic protoporphyria (EPP).

EPP results in the accumulation of protoporphyrins in red blood cells that causes acute, painful, non-blistering photosensitivity (exposure to sunlight).

Clinuvel isn't settling at that, though. It is also looking to expand the usage of Scenesse beyond EPP into vitiligo, XP, VP and stroke. In addition, it is developing additional melanocortin pharmaceuticals and launching a range of topical photo cosmetic consumer products.

In light of the above, the broker believes that the ASX 300 healthcare share is well-positioned for strong growth in the coming years. It commented:

We expect continued free cash flow growth in the near-term without any competition in EPP for at least three years. Clinuvel has multiple development streams ongoing to drive medium to long-term growth, for which we expect approval of Scenesse in vitiligo (~FY28) and launch of Neuracthel (~FY27) to be the largest potential growth drivers.

Big gains ahead for Clinuvel shares

The note reveals that the broker has a buy rating and a $24 price target on Clinuvel's shares.

Based on its current share price of $14.76, this implies a potential upside of almost 63% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »